Grant: Operating Grant: COVID-19 Rapid Research Funding Opportunity - Therapeutics
University of Alberta
$0.00
Broad-spectrum Antiviral Nasal Spray to Prevent and treat Infection by SARS-CoV2 and Seasonal Respiratory Viruses in High Risk Patients and Health Care Providers
EF 2020-21
Résumé
Respiratory virus infections kill hundreds of thousands of people a year around the World. During pandemics this number can increase by over 100-fold. We are developing a nasal spray that has a compound in it that is antiviral against a broad spectrum of different pandemic and seasonal viruses. This antiviral, that we have named RespVirex targets the central replication engine of most viruses, called the polymerase. That means that if the central engine is stopped then the infection is slowed or it is prevented entirely. The throat is the first place that respiratory viruses take hold in the body. Therefore, we are developing RespVirex into a nasal/throat spray and aerosol that can be conveniently dosed by health care professionals and high risk patients to protect them from a broad range of viruses that circulate every flu season and during pandemics. RespVirex is being tested by an international team across Canada and at the Institute Pasteur in Senegal to test its usefulness on African SARS-CoV2 and other tropical viral infections.
Programme
Operating Grant: COVID-19 Rapid Research Funding Opportunity - Therapeutics
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
429479
Name
Marchant David J
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
International Development Research Centre (Ottawa)
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
COVID-19 Rapid Research - Therapeutics
Projecttitle
Broad-spectrum Antiviral Nasal Spray to Prevent and treat Infection by SARS-CoV2 and Seasonal Respiratory Viruses in High Risk Patients and Health Care Providers
Programtype2
Operating Grants
Orgnameinp2
University of Alberta
Cihramount2
$0
Cihrequipment2
$0
Programname2
Operating Grant: COVID-19 Rapid Research Funding Opportunity - Therapeutics
Keyworddelim
Antiviral; Broad Spectrum; Nasal Spray; Polymerase; Prophylactic; Sars-Cov2; Therapeutic
Abstract
Respiratory virus infections kill hundreds of thousands of people a year around the World. During pandemics this number can increase by over 100-fold. We are developing a nasal spray that has a compound in it that is antiviral against a broad spectrum of different pandemic and seasonal viruses. This antiviral, that we have named RespVirex targets the central replication engine of most viruses, called the polymerase. That means that if the central engine is stopped then the infection is slowed or it is prevented entirely. The throat is the first place that respiratory viruses take hold in the body. Therefore, we are developing RespVirex into a nasal/throat spray and aerosol that can be conveniently dosed by health care professionals and high risk patients to protect them from a broad range of viruses that circulate every flu season and during pandemics. RespVirex is being tested by an international team across Canada and at the Institute Pasteur in Senegal to test its usefulness on African SARS-CoV2 and other tropical viral infections.
Competitiondate
202005
Approvedterm2
1 yr 0 mth
Pinamesdelim
Marchant, David J; West, Frederick G
Approvedterm
1 an 0 mois
